



The Role of PET Imaging in Oncology: New Advancements in Clinical and Research Setting

Guest Editors:

Dr. Pierpaolo Alongi

Nuclear Medicine Unit, A.R.N.A.S.
Ospedale Civico Di Cristina
Benfratelli, 90127 Palermo, Italy

Dr. Desiree Deandreis

Department of Medical Sciences,
Division of Nuclear Medicine,
University of Turin, AOU Città
della Salute e della Scienza,
Turin, Italy

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editors

PET imaging has become the most relevant diagnostic tool in the oncology field. Several radiopharmaceuticals have been progressively evaluated in the clinical scenario for different diseases. In the last 15 years, 18F-FDG PET/CT revolutionized staging and restaging in the most aggressive neoplasms, with particular regard for the early assessment of recurrent metastatic disease and response to therapy evaluation. The advent of precision therapy conferred PET imaging a crucial role in clinical management. Other radiotracers, such as 68Ga-Dotatate/tate/noc and 68Ga/18F-PSMA, have demonstrated high accuracy for neuroendocrine and prostate tumors, respectively, also opening a new era of functional imaging guiding radioligand therapy.

New technological and radiopharmaceutical developments are currently the objective of future research. This Special Issue will focus on new advancements of PET imaging in oncology (PET/CT, PET/MRI) in clinical and research settings, also evaluating the novel application of artificial intelligence.

We invite authors to submit contributions that provide novel findings or reviews that comprehensively highlight the latest discoveries in the field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)